LIVIVO - Search results -

Search results

Result 1 - 10 of total 339

Search options

Article: Review article: the limitations of corticosteroid therapy in Crohn's disease.

Rutgeerts, P J

2001 Volume 15, Issue 10, Page(s) 1515–1525

Abstract: Corticosteroids are highly effective in inducing clinical remission in patients with active Crohn's disease. However, the role of corticosteroids in the treatment of this disease is primarily ameliorative because they are ineffective in maintaining ... ...

Abstract	Corticosteroids are highly effective in inducing clinical remission in patients with active Crohn's disease. However, the role of corticosteroids in the treatment of this disease is primarily ameliorative because they are ineffective in maintaining remission or healing mucosal lesions. Nearly half of the patients who initially respond to corticosteroid therapy develop a dependency on corticosteroids or have a relapse within 1 year. In addition, use of these agents is often limited by a relatively high risk of serious adverse effects that can involve nearly every major body system. These effects include: bone loss, which can develop with even short-term and low-dose corticosteroid therapy; metabolic complications such as glucose intolerance and diabetes mellitus; increased intraocular pressure and glaucoma; and potentially lethal infections. To minimize the risk of toxicity, corticosteroids are increasingly recommended for short-term use only at the lowest effective dose to induce remission in patients with moderately to severely active Crohn's disease. Corticosteroid formulations with low systemic bioavailability, such as controlled-release budesonide, may be associated with a lower rate of dermatologic adverse effects but appear to be somewhat less effective than conventional corticosteroids in inducing remission in patients with active Crohn's disease. Immunosuppressive agents such as azathioprine, 6-mercaptopurine, and methotrexate have demonstrated corticosteroid-sparing effects, facilitating the withdrawal of corticosteroids when initiated as maintenance therapy. Infliximab can be used as an alternative to corticosteroids.
MeSH term(s)	Anti-Inflammatory Agents/therapeutic use ; Anti-Inflammatory Agents, Non-Steroidal/therapeutic use ; Crohn Disease/complications ; Crohn Disease/drug therapy ; Crohn Disease/immunology ; Gastrointestinal Agents/therapeutic use ; Glucocorticoids/adverse effects ; Glucocorticoids/therapeutic use ; Humans ; Immunosuppressive Agents/therapeutic use ; Steroids
Chemical Substances	Anti-Inflammatory Agents ; Anti-Inflammatory Agents, Non-Steroidal ; Gastrointestinal Agents ; Glucocorticoids ; Immunosuppressive Agents ; Steroids
Language	English
Publishing date	2001-10
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	639012-2
ISSN	1365-2036 ; 0269-2813 ; 0953-0673
ISSN (online)	1365-2036
ISSN	0269-2813 ; 0953-0673
DOI	10.1046/j.1365-2036.2001.01060.x
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2206: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article: Conventional treatment of Crohn's disease: objectives and outcomes.

Rutgeerts, P J

Inflammatory bowel diseases

2001 Volume 7 Suppl 1, Page(s) S2–8

Abstract: Despite conventional medical and/or surgical intervention, endoscopic and symptomatic relapse is common among individuals with Crohn's disease (CD). Treatment goals have therefore been refocused to include achieving control of active disease and ... ...

Abstract	Despite conventional medical and/or surgical intervention, endoscopic and symptomatic relapse is common among individuals with Crohn's disease (CD). Treatment goals have therefore been refocused to include achieving control of active disease and maintaining remission with agents associated with a minimum of toxic adverse effects. Conventional treatment regimens have been used with varying success in regard to these therapeutic goals. Traditionally, aminosalicylates have been considered effective in inducing a response in some patients with mild-to-moderate CD but have demonstrated little or no long-term benefit in controlled clinical trials. Glucocorticosteroid therapy is associated with higher rates of response in patients with active CD; however, clinical benefits are frequently offset by the common occurrence of corticosteroid-related toxicity. Oral controlled-release budesonide has demonstrated comparable efficacy to prednisolone with less risk for adverse effects, although many questions remain regarding the long-term use of this agent. Response to standard immunosuppressive agents such as azathioprine and 6-mercaptopurine in patients with active disease may require 3 to 6 months from initiation of treatment. These agents are therefore considered most valuable as maintenance therapy, providing consistent long-term benefit in patients with chronic refractory or corticosteroid-dependent disease. Although the incidence of allergic adverse effects is relatively low with azathioprine/6-mercaptopurine, more serious adverse effects, including bone marrow suppression, hepatotoxicity, pancreatitis, and infectious complications, can occur. Limited success in the treatment of perianal disease has been achieved with antibiotics such as metronidazole and the immunosuppressives cyclosporine and azathioprine/6-mercaptopurine. Although broader use of immunosuppressive agents has allowed improvement in the maintenance of remission in patients with CD, long-term safety data with these agents are lacking, concerns about toxicity and the potential risk for neoplasia remain, and attenuation of response with chronic immunosuppressive use can occur. Therefore, innovative therapeutic approaches are needed to meet key treatment goals often not addressed by conventional therapies.
MeSH term(s)	Aminosalicylic Acids/therapeutic use ; Anti-Inflammatory Agents/therapeutic use ; Anti-Inflammatory Agents, Non-Steroidal/therapeutic use ; Azathioprine/therapeutic use ; Budesonide/therapeutic use ; Clinical Trials as Topic ; Crohn Disease/drug therapy ; Crohn Disease/physiopathology ; Humans ; Immunosuppressive Agents/therapeutic use ; Mercaptopurine/therapeutic use ; Mesalamine/therapeutic use ; Methotrexate/therapeutic use ; Prednisone/therapeutic use ; Quality of Life ; Recurrence ; Sulfasalazine/therapeutic use ; Treatment Outcome
Chemical Substances	Aminosalicylic Acids ; Anti-Inflammatory Agents ; Anti-Inflammatory Agents, Non-Steroidal ; Immunosuppressive Agents ; Sulfasalazine (3XC8GUZ6CB) ; Mesalamine (4Q81I59GXC) ; Budesonide (51333-22-3) ; Mercaptopurine (E7WED276I5) ; Azathioprine (MRK240IY2L) ; Prednisone (VB0R961HZT) ; Methotrexate (YL5FZ2Y5U1)
Language	English
Publishing date	2001-05
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	1340971-2
ISSN	1536-4844 ; 1078-0998
ISSN (online)	1536-4844
ISSN	1078-0998
DOI	10.1002/ibd.3780070503
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4530: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Immunogenicity of Golimumab and its Clinical Relevance in Patients With Ulcerative Colitis.

Adedokun, Omoniyi J / Gunn, George R / Leu, Jocelyn H / Gargano, Cynthia / Xu, Zhenhua / Sandborn, William J / Rutgeerts, Paul / Shankar, Gopi

Inflammatory bowel diseases

2019 Volume 25, Issue 9, Page(s) 1532–1540

Abstract: Background: Antidrug antibody (ADA) detection with standard bridging enzyme immunoassays (EIA) can yield false-negative results or underestimate titers through drug interference. A more sensitive assay was needed to determine clinical impact of ... ...

Abstract	Background: Antidrug antibody (ADA) detection with standard bridging enzyme immunoassays (EIA) can yield false-negative results or underestimate titers through drug interference. A more sensitive assay was needed to determine clinical impact of antigolimumab antibodies. Methods: A high-sensitivity, drug-tolerant EIA (DT-EIA) was developed and cross-validated against the original EIA, and samples from induction/maintenance studies in golimumab-treated patients with ulcerative colitis were analyzed for ADAs using both methods. Immunogenicity results were compared, and pharmacokinetic, efficacy, and safety associations were evaluated. Results: An 8-fold increase in ADA-positive patients (21.8% DT-EIA vs 2.8% EIA) reflected DT-EIA improved sensitivity and drug tolerance. Most newly detected ADA-positive patients (using DT-EIA) had low antibody titers, whereas most with high antibody titers were ADA-positive with original EIA. With DT-EIA, week 44 median trough serum golimumab concentrations among ADA-positive patients were approximately half vs ADA-negative (0.51 vs 0.85 µg/mL [50 mg q4w]; 0.85 vs 1.60 µg/mL [100 mg q4w]). Antidrug antibody impact on golimumab concentrations was more notable at titers ≥1:100. During induction, ADAs had no notable impact on efficacy. During maintenance, proportions of patients maintaining clinical response through week 54 were lower using DT-EIA: 38.1% ADA-positive and 52.8% ADA-negative. Antidrug antibody status had no impact on injection-site reaction incidence. Conclusions: A more sensitive DT-EIA identified higher proportions of ADA-positive patients. A trend of decreasing drug concentrations with increasing ADA titers was observed. Pharmacokinetic impact was better elucidated with DT-EIA. Although development of ADA did not preclude efficacy, a trend toward decreased efficacy in ADA-positive vs ADA-negative patients was observed during maintenance treatment. Antidrug antibody status did not impact safety.
MeSH term(s)	Antibodies/analysis ; Antibodies/immunology ; Antibodies, Monoclonal/pharmacokinetics ; Antibodies, Monoclonal/therapeutic use ; Colitis, Ulcerative/blood ; Colitis, Ulcerative/drug therapy ; Colitis, Ulcerative/immunology ; Drug Tolerance/immunology ; Humans ; Immunoassay ; Prognosis
Chemical Substances	Antibodies ; Antibodies, Monoclonal ; golimumab (91X1KLU43E)
Language	English
Publishing date	2019-02-12
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	1340971-2
ISSN	1536-4844 ; 1078-0998
ISSN (online)	1536-4844
ISSN	1078-0998
DOI	10.1093/ibd/izz003
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4530: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Review article: efficacy of infliximab in Crohn's disease--induction and maintenance of remission.

Rutgeerts, P J

Alimentary pharmacology & therapeutics

1999 Volume 13 Suppl 4, Page(s) 9–15; discussion 38

Abstract: The primary goals of treating patients with Crohn's disease are to induce a clinical remission, maintain the remission, and prevent associated complications. Various treatment regimens for patients with Crohn's disease induce a response and remission; ... ...

Abstract	The primary goals of treating patients with Crohn's disease are to induce a clinical remission, maintain the remission, and prevent associated complications. Various treatment regimens for patients with Crohn's disease induce a response and remission; however, most prove ineffective for maintenance of the clinical effect. A therapeutic agent that can induce and maintain remission, while promoting the restoration of intestinal mucosa, would prove to be most beneficial in such a patient population. Several studies with infliximab have clinically demonstrated that the antitumour necrosis factor-alpha therapy rapidly reduced the signs and symptoms in patients with moderate-to-severe Crohn's disease. In acute studies with the chimeric monoclonal antibody, clinical benefit was associated with healing and reduction of inflammation in the bowel mucosal tissue. In a maintenance study, retreatment with infliximab maintained remission of the active disease. Additionally, treatment with the lowest infusion dose of infliximab (5 mg/kg) provided a high degree of clinical benefit with a long-term outcome.
MeSH term(s)	Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/therapeutic use ; Crohn Disease/drug therapy ; Crohn Disease/immunology ; Dose-Response Relationship, Drug ; Gastrointestinal Agents/administration & dosage ; Gastrointestinal Agents/therapeutic use ; Humans ; Infliximab ; Infusions, Intravenous ; Intestinal Mucosa/drug effects ; Intestinal Mucosa/pathology ; Randomized Controlled Trials as Topic ; Remission Induction ; Tumor Necrosis Factor-alpha/antagonists & inhibitors ; Tumor Necrosis Factor-alpha/immunology
Chemical Substances	Antibodies, Monoclonal ; Gastrointestinal Agents ; Tumor Necrosis Factor-alpha ; Infliximab (B72HH48FLU)
Language	English
Publishing date	1999-12-01
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	639012-2
ISSN	1365-2036 ; 0269-2813 ; 0953-0673
ISSN (online)	1365-2036
ISSN	0269-2813 ; 0953-0673
DOI	10.1046/j.1365-2036.1999.00025.x
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2206: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Early Dose Optimisation of Golimumab in Nonresponders to Induction Treatment for Ulcerative Colitis Is Effective and Supported by Pharmacokinetic Data.

Philip, George / Cornillie, Freddy / Adedokun, J Omoniyi / Melsheimer, Richard / Rutgeerts, Paul / Colombel, Jean-Frédéric / Marano, Colleen

Journal of Crohn's & colitis

2019 Volume 13, Issue 10, Page(s) 1257–1264

Abstract: Background and aims: In nonresponders to golimumab induction for ulcerative colitis, we assessed clinical response rates and golimumab serum concentrations when the 100-mg dose was used early in the course of maintenance.: Methods: This post-hoc ... ...

Abstract	Background and aims: In nonresponders to golimumab induction for ulcerative colitis, we assessed clinical response rates and golimumab serum concentrations when the 100-mg dose was used early in the course of maintenance. Methods: This post-hoc analysis of golimumab maintenance dosing [in the PURSUIT-M study] examined clinical outcomes and golimumab concentrations in early [Week 6] responders and nonresponders to induction, including subgroups based on body weight. Results: In nonresponders to golimumab induction [assessed at Week 6], the 100-mg maintenance dose [starting at Week 6] resulted in a meaningful proportion [28.1%] of patients achieving a partial Mayo response at Week 14. After 1 year of maintenance, clinical outcome [response, remission, mucosal healing, corticosteroid-free state] rates in these "late" [Week 14] responders were similar to those in early [Week 6] responders. Golimumab concentrations in early nonresponders were approximately half those of early responders, suggesting that early nonresponders had more rapid golimumab clearance. Examined by body weight, the early nonresponders weighing <80 kg and receiving 100 mg had golimumab concentrations similar to the early responders [weighing <80 kg or ≥80 kg and receiving 50 mg or 100 mg, respectively]. Conclusions: Early use of the 100-mg maintenance dose leads to positive clinical outcomes in a meaningful proportion of patients who did not respond to golimumab at Week 6. Early nonresponders <80 kg who received the 100-mg maintenance dose achieved adequate golimumab concentrations and a clinically meaningful proportion of these patients had a late clinical response.PURSUIT-M protocol number C0524T18; ClinicalTrials.gov, NCT00488631; EudraCT, 2006-003399-37.
MeSH term(s)	Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/blood ; Antibodies, Monoclonal/pharmacokinetics ; Antibodies, Monoclonal/therapeutic use ; C-Reactive Protein/analysis ; Colitis, Ulcerative/drug therapy ; Feces/chemistry ; Gastrointestinal Agents/administration & dosage ; Gastrointestinal Agents/blood ; Gastrointestinal Agents/pharmacology ; Gastrointestinal Agents/therapeutic use ; Humans ; Leukocyte L1 Antigen Complex/analysis ; Remission Induction/methods ; Treatment Outcome ; Tumor Necrosis Factor-alpha/antagonists & inhibitors
Chemical Substances	Antibodies, Monoclonal ; Gastrointestinal Agents ; Leukocyte L1 Antigen Complex ; Tumor Necrosis Factor-alpha ; C-Reactive Protein (9007-41-4) ; golimumab (91X1KLU43E)
Language	English
Publishing date	2019-03-07
Publishing country	England
Document type	Journal Article ; Randomized Controlled Trial
ZDB-ID	2390120-2
ISSN	1876-4479 ; 1873-9946
ISSN (online)	1876-4479
ISSN	1873-9946
DOI	10.1093/ecco-jcc/jjz052
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6634: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn's Disease.

Li, Katherine / Friedman, Joshua R / Chan, Daphne / Pollack, Paul / Yang, Feifei / Jacobstein, Douglas / Brodmerkel, Carrie / Gasink, Christopher / Feagan, Brian G / Sandborn, William J / Rutgeerts, Paul / De Hertogh, Gert

Gastroenterology

2019 Volume 157, Issue 4, Page(s) 1019–1031.e7

Abstract: ... significantly reduced after ustekinumab induction treatment (from 10.4 ± 7.0 to 7.1 ± 5.9; P < .001) but not ... from 7.1 ± 6.2 to 5.2 ± 4.2; P < .0001) but not in those given ustekinumab every 12 weeks (from 6.1 ± 5.7 ... placebo (0% and 22% in the randomized and pooled populations, respectively) (P = .0137 for every 8 weeks ...

Abstract	Background & aims: Although ustekinumab is an effective therapy for moderate to severe Crohn's disease (CD), its effects on the microscopic manifestations of CD are unknown. Methods: We evaluated the effects of ustekinumab on histologic CD activity in an analysis of data from 251 participants in phase 3 induction and maintenance studies. Two endoscopic biopsy samples were collected at weeks 0, 8, and 44 from the ileum, splenic flexure, and rectum (18 biopsy samples from each patient). Histologic activity was assessed based on global histology activity scores (GHASs). Results: At week 8, the mean GHAS was significantly reduced after ustekinumab induction treatment (from 10.4 ± 7.0 to 7.1 ± 5.9; P < .001) but not in patients who received placebo (from 9.2 ± 6.4 to 7.8 ± 6.2). At week 44 in the randomized maintenance therapy population, the mean GHAS remained reduced from week 8 in patients who received subcutaneous ustekinumab (90 mg every 8 weeks; from 7.4 ± 7.7 to 6.1 ± 4.7) but not every 12 weeks (from 5.3 ± 3.9 to 8.7 ± 4.1) or placebo (from 9.2 ± 3.8 to 10.9 ± 7.1). In the pooled (randomized and nonrandomized) maintenance therapy population, histologic improvement continued in patients given ustekinumab every 8 weeks (from 7.1 ± 6.2 to 5.2 ± 4.2; P < .0001) but not in those given ustekinumab every 12 weeks (from 6.1 ± 5.7 to 7.2 ± 5.1) or placebo (from 8.2 ± 4.2 to 8.9 ± 6.8). A significantly greater proportion of patients achieved histologic response (≥50% decrease in GHAS from baseline) at week 44 if they received ustekinumab every 8 weeks (50% in the randomized maintenance population and 54% in the pooled maintenance population) compared with every 12 weeks (17% and 39% in the randomized and pooled populations, respectively) or placebo (0% and 22% in the randomized and pooled populations, respectively) (P = .0137 for every 8 weeks vs placebo and P = .3529 for every 12 weeks vs placebo in the randomized population; P = .0168 for every 8 weeks vs placebo and P = .3069 for every 12 weeks vs placebo in the pooled population). Regional and overall mean GHASs correlated with the simple endoscopic score for CD (r = .6255, P < .0001). Multivariate analysis found an association between histologic improvement and endoscopic or histologic burden at baseline. Conclusions: In an analysis of data from participants in phase 3 induction and maintenance trials, we found histologic improvement in a greater proportion of patients given ustekinumab vs placebo. The largest improvements occurred in patients who received ustekinumab maintenance therapy every 8 weeks. ClinicalTrials.gov nos. NCT01369329, NCT01369342, and NCT01369355.
MeSH term(s)	Adult ; Anti-Inflammatory Agents/administration & dosage ; Anti-Inflammatory Agents/adverse effects ; Biopsy ; Crohn Disease/drug therapy ; Crohn Disease/pathology ; Drug Administration Schedule ; Endoscopy, Gastrointestinal ; Female ; Gastrointestinal Agents/administration & dosage ; Gastrointestinal Agents/adverse effects ; Humans ; Induction Chemotherapy ; Intestinal Mucosa/drug effects ; Intestinal Mucosa/pathology ; Maintenance Chemotherapy ; Male ; Middle Aged ; Remission Induction ; Time Factors ; Treatment Outcome ; Ustekinumab/administration & dosage ; Ustekinumab/adverse effects ; Wound Healing/drug effects
Chemical Substances	Anti-Inflammatory Agents ; Gastrointestinal Agents ; Ustekinumab (FU77B4U5Z0)
Language	English
Publishing date	2019-07-04
Publishing country	United States
Document type	Clinical Trial, Phase III ; Comparative Study ; Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	80112-4
ISSN	1528-0012 ; 0016-5085
ISSN (online)	1528-0012
ISSN	0016-5085
DOI	10.1053/j.gastro.2019.06.037
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui V Zs.44: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 572: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Measurements of Atmospheric Proteinaceous Aerosol in the Arctic Using a Selective UHPLC/ESI-MS/MS Strategy.

Mashayekhy Rad, Farshid / Zurita, Javier / Gilles, Philippe / Rutgeerts, Laurens A J / Nilsson, Ulrika / Ilag, Leopold L / Leck, Caroline

Journal of the American Society for Mass Spectrometry

2018 Volume 30, Issue 1, Page(s) 161–173

Abstract: In this article, an analytical methodology to investigate the proteinaceous content in atmospheric size-resolved aerosols collected at the Zeppelin observatory (79 °N, 12 °E) at Ny Ålesund, Svalbard, from September to December 2015, is proposed. ... ...

Abstract	In this article, an analytical methodology to investigate the proteinaceous content in atmospheric size-resolved aerosols collected at the Zeppelin observatory (79 °N, 12 °E) at Ny Ålesund, Svalbard, from September to December 2015, is proposed. Quantitative determination was performed after acidic hydrolysis using ultrahigh-performance liquid chromatography in reversed-phase mode coupled to electrospray ionization tandem mass spectrometry. Chromatographic separation, as well as specificity in the identification, was achieved by derivatization of the amino acids with N-butyl nicotinic acid N-hydroxysuccinimide ester prior to the analysis. The chromatographic run was performed within 11 min and instrumental levels of detection (LODs) were between 0.2 and 8.1 pg injected on the column, except for arginine which exhibited an LOD of 37 pg. Corresponding method LODs were between 0.01 and 1.9 fmol/m
MeSH term(s)	Aerosols/analysis ; Air/analysis ; Amino Acids/analysis ; Amino Acids/chemistry ; Arctic Regions ; Atmosphere ; Chromatography, High Pressure Liquid/methods ; Hydrolysis ; Limit of Detection ; Niacin/analogs & derivatives ; Niacin/pharmacology ; Norway ; Particle Size ; Proteins/chemistry ; Spectrometry, Mass, Electrospray Ionization/methods ; Succinimides/pharmacology ; Tandem Mass Spectrometry/methods
Chemical Substances	Aerosols ; Amino Acids ; Proteins ; Succinimides ; Niacin (2679MF687A)
Language	English
Publishing date	2018-07-17
Publishing country	United States
Document type	Journal Article
ZDB-ID	1073671-2
ISSN	1879-1123 ; 1044-0305
ISSN (online)	1879-1123
ISSN	1044-0305
DOI	10.1007/s13361-018-2009-8
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4618: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 241: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn's Disease Studies.

Panaccione, Remo / Löfberg, Robert / Rutgeerts, Paul / Sandborn, William J / Schreiber, Stefan / Berg, Sofie / Maa, Jen-Fue / Petersson, Joel / Robinson, Anne M / Colombel, Jean-Frederic

Journal of Crohn's & colitis

2019 Volume 13, Issue 6, Page(s) 725–734

Abstract: ... of patients achieving CDAI remission was higher in adalimumab- versus placebo-treated patients [p <0.001] and ... subgroups [≥1-<2 years: 31.0%; 2-≤5 years: 23.1%; >5 years: 23.6%, Cochran-Armitage p = 0.026 ...

Abstract	Background and aims: Analyses of Crohn's Disease [CD] studies of anti-TNF agents, including adalimumab, have reported higher remission rates among patients with shorter disease duration. To further explore the relationship between disease duration and clinical efficacy, we analysed a larger patient cohort. Methods: Data were pooled from 10 clinical trials in patients with moderately to severely active CD who received treatment with either adalimumab or placebo. Analyses of efficacy using Crohn's Disease Activity Index [CDAI] endpoints [remission, clinical response [CR]-70, CR-100, patient-reported outcome [PRO] remission] or Harvey-Bradshaw Index [HBI] endpoints [remission/response] were conducted for induction and maintenance treatment periods. Logistic regression was used for comparisons between adalimumab and placebo treatment. Cochran-Armitage trend tests were used for comparisons between disease-duration subgroups [<1 year, ≥1-<2 years, 2-≤5 years, and >5 years]. Results: During induction, the proportion of patients achieving CDAI remission was higher in adalimumab- versus placebo-treated patients [p <0.001] and was highest [adalimumab: 45.8%] in the <1 year subgroup compared with longer disease-duration subgroups [≥1-<2 years: 31.0%; 2-≤5 years: 23.1%; >5 years: 23.6%, Cochran-Armitage p = 0.026]. In the majority of maintenance treatment analyses, patients with <1 year disease duration had the highest efficacy responses, with statistically significant differences in remission rates across disease-duration subgroups. Conclusions: This analysis demonstrates that earlier initiation of adalimumab treatment shortly after diagnosis in patients with moderately to severely active CD leads to improved long-term clinical outcomes.
MeSH term(s)	Adalimumab/adverse effects ; Adalimumab/therapeutic use ; Adult ; Anti-Inflammatory Agents/adverse effects ; Anti-Inflammatory Agents/therapeutic use ; Clinical Trials as Topic/statistics & numerical data ; Crohn Disease/drug therapy ; Female ; Humans ; Male ; Time Factors ; Treatment Outcome ; Tumor Necrosis Factor-alpha/antagonists & inhibitors
Chemical Substances	Anti-Inflammatory Agents ; Tumor Necrosis Factor-alpha ; Adalimumab (FYS6T7F842)
Language	English
Publishing date	2019-05-17
Publishing country	England
Document type	Journal Article
ZDB-ID	2390120-2
ISSN	1876-4479 ; 1873-9946
ISSN (online)	1876-4479
ISSN	1873-9946
DOI	10.1093/ecco-jcc/jjy223
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6634: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Robust scalable synthesis of a bis-urea derivative forming thixotropic and cytocompatible supramolecular hydrogels

Rutgeerts, Laurens A. J. / Soultan, Al Halifa / Subramani, Ramesh / Toprakhisar, Burak / Ramon, H. / Paderes, Monissa C. / De Borggraeve, Wim M. / Patterson, Jennifer

Chemical communications. 2019 June 20, v. 55, no. 51 p.7323-7326

2019

Abstract: Synthetic hydrogels address a need for affordable, industrially scalable scaffolds for tissue engineering. Herein, a novel low molecular weight gelator is reported that forms self-healing supramolecular hydrogels. Its robust synthesis can be performed in ...

Abstract	Synthetic hydrogels address a need for affordable, industrially scalable scaffolds for tissue engineering. Herein, a novel low molecular weight gelator is reported that forms self-healing supramolecular hydrogels. Its robust synthesis can be performed in a solvent-free manner using ball milling. Strikingly, encapsulated cells spread and proliferate without specific cell adhesion ligands in the nanofibrous material.
Keywords	cell adhesion ; chemical reactions ; encapsulation ; hydrogels ; ligands ; milling ; molecular weight ; nanofibers ; tissue engineering
Language	English
Dates of publication	2019-0620
Size	p. 7323-7326.
Publishing place	The Royal Society of Chemistry
Document type	Article ; Online
ZDB-ID	1472881-3
ISSN	1364-548X ; 1359-7345 ; 0009-241X
ISSN (online)	1364-548X
ISSN	1359-7345 ; 0009-241X
DOI	10.1039/c9cc02927c
Database	NAL-Catalogue (AGRICOLA)

Order via subito

Article ; Online: Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.

Rutgeerts, Paul / Gasink, Christopher / Chan, Daphne / Lang, Yinghua / Pollack, Paul / Colombel, Jean-Frederic / Wolf, Douglas C / Jacobstein, Douglas / Johanns, Jewel / Szapary, Philippe / Adedokun, Omoniyi J / Feagan, Brian G / Sandborn, William J

Gastroenterology

2018 Volume 155, Issue 4, Page(s) 1045–1058

Abstract: ... reduction of 2.8 in patients given ustekinumab vs a reduction of 0.7 points in patients given placebo; P ... in patients given ustekinumab (for combined groups, a reduction of 2.5; P = .176 and for every 8 weeks ... a reduction of 3.1; P = .107) than patients given placebo (reduction of 1.9 points). Maintenance results were ...

Abstract	Background & aims: We evaluated the ability of ustekinumab, a monoclonal antibody against the p40 subunit of interleukins 12 and 23, to induce endoscopic healing in patients with moderate to severe Crohn's disease (CD). Methods: We performed an endoscopy substudy of 334 patients with moderate to severe CD participating in 3 randomized controlled phase 3 studies to determine the safety and efficacy of ustekinumab induction and maintenance therapy. All patients underwent colonoscopy at baseline and week 8 of the induction studies and at week 44 of the maintenance study; all colonoscopies were assessed by a blinded central reader. During the induction studies, patients were randomly assigned to groups given intravenous ustekinumab (130 mg or 6 mg/kg) or placebo. At the baseline time point of the maintenance study (week 8 of the induction studies), patients with a clinical response to ustekinumab were randomly assigned to groups given subcutaneous ustekinumab (90 mg every 12 weeks or 8 weeks) or placebo. Additional maintenance analysis populations were patients who did not respond to ustekinumab or placebo during the induction studies, and patients who responded to placebo during the induction studies; we performed a post-hoc pooled analysis of randomly assigned and non-randomly assigned patients of the maintenance study. We analyzed data from patients with an ulcer in at least 1 segment at baseline of the induction studies. The primary end point was change in the Simplified Endoscopic Activity Score for Crohn's Disease (SES-CD), from baseline, at week 8. We also assessed the efficacy of maintenance therapy. Results: Patients given ustekinumab had a greater reduction in SES-CD from the induction baseline time point until week 8 than placebo (reduction of 2.8 in patients given ustekinumab vs a reduction of 0.7 points in patients given placebo; P = .012). Results were similar among patients in different induction studies and patients given different doses of ustekinumab. At week 44, reductions in the SES-CD from the induction baseline were greater in patients given ustekinumab (for combined groups, a reduction of 2.5; P = .176 and for every 8 weeks, a reduction of 3.1; P = .107) than patients given placebo (reduction of 1.9 points). Maintenance results were similar for the larger pooled post-hoc analysis. Conclusions: In an analysis of data from 3 trials of patients with moderate to severe CD, ustekinumab (intravenous induction and subcutaneous maintenance) reduces SES-CD compared with placebo. We observed significant reductions in endoscopic disease activity at week 8 of induction therapy with ustekinumab. (ClinicalTrials.gov numbers, NCT01369329, NCT01369342, and NCT01369355).
MeSH term(s)	Administration, Intravenous ; Adult ; Anti-Inflammatory Agents/administration & dosage ; Anti-Inflammatory Agents/adverse effects ; Anti-Inflammatory Agents/pharmacokinetics ; Colon/drug effects ; Colon/pathology ; Colonoscopy ; Crohn Disease/drug therapy ; Crohn Disease/pathology ; Female ; Gastrointestinal Agents/administration & dosage ; Gastrointestinal Agents/adverse effects ; Gastrointestinal Agents/pharmacokinetics ; Humans ; Induction Chemotherapy ; Maintenance Chemotherapy ; Male ; Middle Aged ; Predictive Value of Tests ; Prospective Studies ; Remission Induction ; Severity of Illness Index ; Time Factors ; Treatment Outcome ; Ustekinumab/administration & dosage ; Ustekinumab/adverse effects ; Ustekinumab/pharmacokinetics ; Wound Healing/drug effects
Chemical Substances	Anti-Inflammatory Agents ; Gastrointestinal Agents ; Ustekinumab (FU77B4U5Z0)
Language	English
Publishing date	2018-08-29
Publishing country	United States
Document type	Clinical Trial, Phase III ; Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	80112-4
ISSN	1528-0012 ; 0016-5085
ISSN (online)	1528-0012
ISSN	0016-5085
DOI	10.1053/j.gastro.2018.06.035
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui V Zs.44: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 572: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito